These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19460677)

  • 1. Radiographic appearance of endoscopic duodenal-jejunal bypass liner for treatment of obesity and type 2 diabetes.
    Levine A; Ramos A; Escalona A; Rodriguez L; Greve JW; Janssen I; Rothstein R; Nepomnayshy D; Gersin KS; Melanson D; Lamport R; Fishman E; Malomo K; Kaplan LM; Neto MG
    Surg Obes Relat Dis; 2009; 5(3):371-4. PubMed ID: 19460677
    [No Abstract]   [Full Text] [Related]  

  • 2. [EndoBarrier as a treatment for obesity and diabetes].
    Greve JWM; Bouvy ND
    Ned Tijdschr Geneeskd; 2018; 162():D2268. PubMed ID: 29519261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
    Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
    Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
    Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic Therapeutic Option for Weight Loss and Control of Type 2 Diabetes: the Duodenal-Jejunal Bypass Liner.
    de Moura EG; Orso IR; Martins BC; Lopes GS
    Surg Technol Int; 2015 May; 26():115-9. PubMed ID: 26054998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery.
    Tarnoff M; Rodriguez L; Escalona A; Ramos A; Neto M; Alamo M; Reyes E; Pimentel F; Ibanez L
    Surg Endosc; 2009 Mar; 23(3):650-6. PubMed ID: 19067075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.
    Escalona A; Pimentel F; Sharp A; Becerra P; Slako M; Turiel D; Muñoz R; Bambs C; Guzmán S; Ibáñez L; Gersin K
    Ann Surg; 2012 Jun; 255(6):1080-5. PubMed ID: 22534421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review.
    Zechmeister-Koss I; Huić M; Fischer S;
    Obes Surg; 2014 Feb; 24(2):310-23. PubMed ID: 24293185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
    Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
    J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier®) on Gastric Emptying in Obese and Type 2 Diabetic Patients.
    de Moura EG; Lopes GS; Martins BC; Orso IR; Coutinho AM; de Oliveira SL; Sakai P; Galvão-Neto Mdos P; Santo MA; Sapienza MT; Cecconello I; Buchpiguel CA
    Obes Surg; 2015 Sep; 25(9):1618-25. PubMed ID: 25691349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity.
    Escalona A; Yáñez R; Pimentel F; Galvao M; Ramos AC; Turiel D; Boza C; Awruch D; Gersin K; Ibáñez L
    Surg Obes Relat Dis; 2010 Mar; 6(2):126-31. PubMed ID: 20359665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
    van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
    Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service.
    Ryder REJ; Yadagiri M; Burbridge W; Irwin SP; Gandhi H; Bashir T; Allden RA; Wyres M; Cull M; Bleasdale JP; Fogden EN; Anderson MR; Sen Gupta P
    Diabet Med; 2022 Jul; 39(7):e14827. PubMed ID: 35285080
    [No Abstract]   [Full Text] [Related]  

  • 15. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?
    Leventi E; Günthert SJ; Stier C; Staikov P; Stein J; Farrag K
    Obes Surg; 2019 May; 29(5):1690-1693. PubMed ID: 30826914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases.
    Cohen RV; Schiavon CA; Pinheiro JS; Correa JL; Rubino F
    Surg Obes Relat Dis; 2007; 3(2):195-7. PubMed ID: 17386401
    [No Abstract]   [Full Text] [Related]  

  • 19. Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide.
    Ryder REJ; Laubner K; Benes M; Haluzik M; Munro L; Frydenberg H; Teare JP; Ruban A; Fishman S; Santo E; Stengel R; De Jonge C; Greve JW; Cohen RV; Aboud CM; Holtmann GJ; Rich G; McMaster JJ; Battelino T; Kotnik P; Byrne JP; Mason JC; Bessell J; Bascomb J; Kow L; Collins J; Chisholm J; Pferschy PN; Sourij H; Cull ML; Wyres MC; Drummond R; McGowan B; Amiel SA; Yadagiri M; Sen Gupta P; Aberle J; Seufert J
    Diabetes Care; 2023 Apr; 46(4):e89-e91. PubMed ID: 36716004
    [No Abstract]   [Full Text] [Related]  

  • 20. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.